Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: A potent targeted anticoagulant

Yi Heng So; Huan Tsung Chang; Wei Jane Chiu; Chih Ching Huang

doi:10.1039/c4bm00156g

Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: A potent targeted anticoagulant

Yi Heng So
, Huan Tsung Chang
, Wei Jane Chiu
, Chih Ching Huang^*

^*Corresponding author for this work

National Taiwan Ocean University
National Taiwan University
Kaohsiung Medical University

Research output: Contribution to journal › Journal Article › peer-review

15 Scopus citations

Abstract

Graphene oxide (GO) modified with 29-mer thrombin-binding-aptamer- conjugated gold nanoparticles (TBA₂₉-Au NPs/GO) can synergistically inhibit the thrombin-mediated cleavage of fibrinogen to fibrin. To further improve anticoagulation efficiency in human plasma, TBA₂₉-Au NPs/heparin/GO has been prepared from TBA₂₉-Au NPs/GO and heparin that can also bind thrombin. The dose-dependence of thrombin clotting time (TCT) delay caused by TBA₂₉-Au NPs/heparin/GO is 21.4, 17.0 and >100 times higher than that caused by the TBA₂₉-Au NPs, TBA ₂₉-Au NPs/GO and commercially available drugs (heparin, argatroban, hirudin or warfarin), respectively. This journal is

Original language	English
Pages (from-to)	1332-1337
Number of pages	6
Journal	Biomaterials Science
Volume	2
Issue number	10
DOIs	https://doi.org/10.1039/c4bm00156g
State	Published - 10 2014
Externally published	Yes

Access to Document

10.1039/c4bm00156g

Cite this

@article{a700372c0ef041caa0567f8713316c0e,

title = "Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: A potent targeted anticoagulant",

abstract = "Graphene oxide (GO) modified with 29-mer thrombin-binding-aptamer- conjugated gold nanoparticles (TBA29-Au NPs/GO) can synergistically inhibit the thrombin-mediated cleavage of fibrinogen to fibrin. To further improve anticoagulation efficiency in human plasma, TBA29-Au NPs/heparin/GO has been prepared from TBA29-Au NPs/GO and heparin that can also bind thrombin. The dose-dependence of thrombin clotting time (TCT) delay caused by TBA29-Au NPs/heparin/GO is 21.4, 17.0 and >100 times higher than that caused by the TBA29-Au NPs, TBA 29-Au NPs/GO and commercially available drugs (heparin, argatroban, hirudin or warfarin), respectively. This journal is",

author = "So, \{Yi Heng\} and Chang, \{Huan Tsung\} and Chiu, \{Wei Jane\} and Huang, \{Chih Ching\}",

year = "2014",

month = oct,

doi = "10.1039/c4bm00156g",

language = "英语",

volume = "2",

pages = "1332--1337",

journal = "Biomaterials Science",

issn = "2047-4830",

publisher = "Royal Society of Chemistry",

number = "10",

}

TY - JOUR

T1 - Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin

T2 - A potent targeted anticoagulant

AU - So, Yi Heng

AU - Chang, Huan Tsung

AU - Chiu, Wei Jane

AU - Huang, Chih Ching

PY - 2014/10

Y1 - 2014/10

N2 - Graphene oxide (GO) modified with 29-mer thrombin-binding-aptamer- conjugated gold nanoparticles (TBA29-Au NPs/GO) can synergistically inhibit the thrombin-mediated cleavage of fibrinogen to fibrin. To further improve anticoagulation efficiency in human plasma, TBA29-Au NPs/heparin/GO has been prepared from TBA29-Au NPs/GO and heparin that can also bind thrombin. The dose-dependence of thrombin clotting time (TCT) delay caused by TBA29-Au NPs/heparin/GO is 21.4, 17.0 and >100 times higher than that caused by the TBA29-Au NPs, TBA 29-Au NPs/GO and commercially available drugs (heparin, argatroban, hirudin or warfarin), respectively. This journal is

AB - Graphene oxide (GO) modified with 29-mer thrombin-binding-aptamer- conjugated gold nanoparticles (TBA29-Au NPs/GO) can synergistically inhibit the thrombin-mediated cleavage of fibrinogen to fibrin. To further improve anticoagulation efficiency in human plasma, TBA29-Au NPs/heparin/GO has been prepared from TBA29-Au NPs/GO and heparin that can also bind thrombin. The dose-dependence of thrombin clotting time (TCT) delay caused by TBA29-Au NPs/heparin/GO is 21.4, 17.0 and >100 times higher than that caused by the TBA29-Au NPs, TBA 29-Au NPs/GO and commercially available drugs (heparin, argatroban, hirudin or warfarin), respectively. This journal is

UR - https://www.scopus.com/pages/publications/84906657689

U2 - 10.1039/c4bm00156g

DO - 10.1039/c4bm00156g

M3 - 文章

AN - SCOPUS:84906657689

SN - 2047-4830

VL - 2

SP - 1332

EP - 1337

JO - Biomaterials Science

JF - Biomaterials Science

IS - 10

ER -

Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: A potent targeted anticoagulant

Abstract

Access to Document

Other files and links

Fingerprint

Cite this